Tyme Technologies (NASDAQ:TYME) announced its earnings results on Monday. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08), MarketWatch Earnings reports.
NASDAQ:TYME opened at $3.08 on Wednesday. The firm has a market cap of $288.93 million, a P/E ratio of -14.67 and a beta of 0.32. Tyme Technologies has a 1-year low of $1.93 and a 1-year high of $4.64.
Several research firms recently weighed in on TYME. Zacks Investment Research lowered Tyme Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, January 10th. BidaskClub raised Tyme Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday, December 5th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Tyme Technologies in a research report on Wednesday, November 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $7.58.
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Recommended Story: Tariff
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.